A surveillance programme for Barrett's oesophagus in a UK general hospital

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 4, 2007, Pages 305-309

  Olithselvan, Arikichenin ^a   Gorard, David A ^a   McIntyre, Alistair S ^a  

^a WYCOMBE HOSPITAL   (United Kingdom)

Author keywords

Barrett's oesophagus; Columnar lined oesophagus; Oesophageal adenocarcinoma; Surveillance

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; FEMALE; GENERAL HOSPITAL; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED KINGDOM;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; BIOPSY; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, GENERAL; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES;

EID: 33947153917     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000252630.96043.b1     Document Type: Article

References (14)

1. Watson A, Heading RC, Shepherd NA. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. Br Soc Gastroenterol 2005.
2. Van der Veen AH, Dees J, Blankensteijn JD. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989; 30:14-18.
3. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215.
4. Murray L, Watson P, Johnston B, Sloan J, Mohan Lal Mainie I, Gavin A. Risks of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003; 327:534-535.
5. MacDonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2002; 321:1252-1255.
6. Sobin LH, Wittekind C, editors. International Union Against Cancer (UICC): TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss; 1997.
7. Wright TA, Gray MR, Morris AI, Gilmore IT, Ellis A, Smart HL, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996; 39:574-579.
8. Bani-Hani K, Sue-Ling H, Johnston D, Axon ATR, Martin IG. Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol 2000; 12:649-654.
9. Fitzgerald RC, Saeed IT, Khoo D, Farthing MJG, Burnham WR. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001; 46:1892-1895.
10. Nilsson J, Skobe V, Johansson J, Willen R, Johnsson F. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand J Gastroenterol 2000; 35:10-16.
11. Iftikhar SY, James PD, Steele RJC, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33:1155-1158.
12. Solaymani-Dodaran M, Logan RFA, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53:1070-1074.
13. Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108:813-822.
14. Fountoulakis A, Zafirellis KD, Dolan K, Dexter SPL, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Brit J Surg 2004; 91:997-1003.